Author Archives: admin

Northvale, New Jersey, Tuesday, December 16, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP) today announced the continued expansion of Elite’s intellectual property protection covering the Company’s abuse deterrent technology with the issuance of a second Canadian Patent, … Continue reading →

Northvale, New Jersey, Wednesday, December 03, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite’s twice daily abuse-deterrent oxycodone product which utilizes Elite’s proprietary pharmacological abuse-deterrent … Continue reading →

Revenues increase by 8% Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST Northvale, New Jersey, Friday, November 14, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche … Continue reading →

Northvale, New Jersey, Friday, October 24, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., … Continue reading →